Attached files
Exhibit 23.1
When the transaction referred to in Note 11 of the notes to the financial statements has been consummated, we will be in a position to render the following consent.
/s/ KPMG LLP
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Aimmune Therapeutics,
Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading Experts in the prospectus.
San Francisco, California
, 2015